Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion

H. Lorberboum-Galski*, R. Lafyatis, J. P. Case, D. FitzGerald, R. L. Wilder, I. Pastan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when adminstered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37°C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.

Original languageAmerican English
Pages (from-to)305-315
Number of pages11
JournalInternational Journal of Immunopharmacology
Volume13
Issue number2-3
DOIs
StatePublished - 1991
Externally publishedYes

Bibliographical note

Funding Information:
*Laboratory of Molecular Biology, Division of Cancer Biology and Diagnosis, National Cancer Institute and +Arthritis and Rheumatism, Connective Tissue Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, U.S.A.

Fingerprint

Dive into the research topics of 'Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion'. Together they form a unique fingerprint.

Cite this